21 related articles for article (PubMed ID: 38531704)
1. Reply to Kentaro Inamura's Letter to the Editor re: Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.05.023.
Feng M; Matoso A; Epstein G; Fong M; Park YH; Gabrielson A; Patel S; Czerniak B; Compérat E; Hoffman-Censits J; Kates M; Kim S; McConkey D; Choi W
Eur Urol; 2024 Apr; 85(4):e122-e123. PubMed ID: 37775361
[No Abstract] [Full Text] [Related]
2. Reply to Andrew J. Vickers' Letter to the Editor re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.003.
Uleri A; Baboudjian M; Diamand R; Ploussard G
Eur Urol; 2024 May; ():. PubMed ID: 38796380
[No Abstract] [Full Text] [Related]
3. Reply to Hein V. Stroomberg, Klaus Brasso, and Andreas Røder's Letter to the Editor re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.003.
Uleri A; Baboudjian M; Diamand R; Ploussard G
Eur Urol; 2024 May; ():. PubMed ID: 38796382
[No Abstract] [Full Text] [Related]
4. Re: Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.05.023.
Wang Z; Zeng S; Xu C
Eur Urol; 2024 Apr; 85(4):e113-e114. PubMed ID: 37919193
[No Abstract] [Full Text] [Related]
5. Re: Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.05.023.
Inamura K
Eur Urol; 2024 Apr; 85(4):e120-e121. PubMed ID: 37696739
[No Abstract] [Full Text] [Related]
6. Re: Roxana Ramos, Ethan Ferguson, Mahmoud Abou Zeinab, et al. Single-port Transvesical Robot-assisted Simple Prostatectomy: Surgical Technique and Clinical Outcomes. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.11.012.
Singh J
Eur Urol; 2024 May; ():. PubMed ID: 38796381
[No Abstract] [Full Text] [Related]
7. Re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.003.
Vickers AJ
Eur Urol; 2024 May; ():. PubMed ID: 38797599
[No Abstract] [Full Text] [Related]
8. Reply to Yudai Ishiyama and Fumihiko Urabe's Letter to the Editor re: Kosuke Takemura, Audreylie Lemelin, Matthew S. Ernst, et al. Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.01.006.
Takemura K; Yuasa T; Choueiri TK; Heng DYC
Eur Urol; 2024 Mar; ():. PubMed ID: 38531704
[No Abstract] [Full Text] [Related]
9. Re: Kosuke Takemura, Audreylie Lemelin, Matthew S. Ernst, et al. Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.01.006.
Ishiyama Y; Urabe F
Eur Urol; 2024 Apr; ():. PubMed ID: 38604930
[No Abstract] [Full Text] [Related]
10. Re: Kosuke Takemura, Matthew S. Ernst, Vishal Navani, et al. Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.10.002.
Ishiyama Y; Urabe F
Eur Urol Oncol; 2024 Jun; 7(3):642-643. PubMed ID: 38238222
[No Abstract] [Full Text] [Related]
11. Reply to Binghao Zhao, Hao Xing, and Wenbin Ma's Letter to the Editor re: Matthew S. Ernst, Vishal Navani, J. Connor Wells, et al. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. Eur Urol. 2023;84:109-116.
Ernst MS; Heng DYC
Eur Urol; 2023 Jul; 84(1):e18-e19. PubMed ID: 37080894
[No Abstract] [Full Text] [Related]
12. Re: Matthew S. Ernst, Vishal Navani, J. Connor Wells, et al. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. Eur Urol 2023;84:109-16.
Saal J; Grünwald V; Klümper N
Eur Urol; 2023 Dec; 84(6):e143-e144. PubMed ID: 37661553
[No Abstract] [Full Text] [Related]
13. Re: Matthew S. Ernst, Vishal Navani, J. Connor Wells, et al. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. Eur Urol. 2023;84:109-116.
Regan MM; Atkins MB; McDermott DF
Eur Urol; 2023 Oct; 84(4):e96-e97. PubMed ID: 37391304
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]